Oncoclínicas Weighs Precautionary Court Move to Shield Against Creditor Claims

Overview

• Oncoclínicas said Wednesday it is assessing a precautionary court measure that would pause creditor collections, and it has not decided whether or when to file.
• The company cited a possible breach of leverage tests in its bond contracts and other loans, with Valor reporting a cap of 3.5 times EBITDA in 2025, a measure of cash earnings.
• In a reply to Brazil's securities regulator CVM, management said it is also studying ways to shore up finances, including possible transactions with third parties.
• Valor reported the court request could come early next week following results due Thursday and an investor call on Friday, though the company has not confirmed that timeline.
• Separately, the firm denied any binding deals with Mak, Lumina, or Starboard, confirmed only a non‑binding offer from Mak and Lumina with terms it called unworkable, and said its sole formal exclusivity is with Porto and Fleury through April 12.